Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 10/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275591 | 0.86 | HDAC4 (0.40) | HDAC4SYKCYP11B1CYP11B2 | |
| SCHEMBL17276348 | 0.83 | PDK2 (0.52) | PDK2HDAC4SYKRBP4 | |
| SCHEMBL17276159 | 0.78 | HDAC4 (0.39) | PDK2HDAC4CYP11B1CYP11B2 | |
| SCHEMBL17276193 | 0.73 | PDK2 (0.45) | PDK2HDAC4SYK | |
| SCHEMBL6285519 | 0.73 | HDAC4 (0.44) | PDK2HDAC4CYP11B1CYP11B2 | |
| SCHEMBL17276351 | 0.71 | PDK2 (0.44) | PDK2HDAC4CYP11B1CYP11B2 | |
| SCHEMBL17276115 | 0.69 | CFTR (0.39) | PDK2RBP4CFTRBDKRB1 | |
| SCHEMBL31367342 | 0.69 | CFTR (0.39) | PDK2RBP4CFTRBDKRB1 | |
| SCHEMBL17276575 | 0.69 | PDK2 (0.48) | PDK2HDAC4RBP4 | |
| SCHEMBL31474036 | 0.68 | SYK (0.35) | PDK2SYKPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | PDK2 1684/4885HDAC4 549/4885SYK 3678/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | PDK2 1684/4885HDAC4 549/4885SYK 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.